Surgical outcomes of patients with gastrointestinal stromal tumors in the era of targeted drug therapy

Journal of Gastrointestinal Surgery

Volumn 12, Issue 11, 2008, Pages 2023-2031

  Nikfarjam, Mehrdad ^a   Kimchi, Eric ^a   Shereef, Serene ^a   Gusani, Niraj J ^a   Jiang, Yixing ^a   Liang, John ^a   Sehmbey, Mandeep ^a   Staveley O'Carroll, Kevin F ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

Disease free survival; Gastrointestinal stromal tumor; Imitinab mesylate; Mitotic rate; Multivisceral resection; Recurrence; Size; Targeted therapy

Indexed keywords

IMATINIB; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; STEM CELL FACTOR RECEPTOR;

ADJUVANT CHEMOTHERAPY; AGED; ARTICLE; CANCER STAGING; COHORT ANALYSIS; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG DELIVERY SYSTEM; DRUG EFFECT; FEMALE; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MORTALITY; NONPARAMETRIC TEST; PATHOLOGY; PROBABILITY; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SURVIVAL; TREATMENT OUTCOME;

AGED; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG DELIVERY SYSTEMS; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL STROMAL TUMORS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM STAGING; PIPERAZINES; PROBABILITY; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 54349083593     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11605-008-0561-4     Document Type: Article

References (40)

1. B Nilsson P Bumming JM Meis-Kindblom 2005 Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era-a population-based study in western Sweden Cancer 103 4 821 829
2. G Tryggvason HG Gislason MK Magnusson JG Jonasson 2005 Gastrointestinal stromal tumors in Iceland, 1990-2003: the icelandic GIST study, a population-based incidence and pathologic risk stratification study Int J Cancer 117 2 289 293
3. Hassan I, You YN, Shyyan R, et al. Surgically managed gastrointestinal stromal tumors: a comparative and prognostic analysis. Ann Surg Oncol 2008;15:4-6.
4. P Bumming H Ahlman J Andersson JM Meis-Kindblom LG Kindblom B Nilsson 2006 Population-based study of the diagnosis and treatment of gastrointestinal stromal tumours Br J Surg 93 7 836 843
5. MT Mazur HB Clark 1983 Gastric stromal tumors. Reappraisal of histogenesis Am J Surg Pathol 7 6 507 519
6. CL Corless JA Fletcher MC Heinrich 2004 Biology of gastrointestinal stromal tumors J Clin Oncol 22 18 3813 3825
7. EH Ng RE Pollock MM Romsdahl 1992 Prognostic implications of patterns of failure for gastrointestinal leiomyosarcomas Cancer 69 6 1334 1341
8. MH Shiu GH Farr DN Papachristou SI Hajdu 1982 Myosarcomas of the stomach: natural history, prognostic factors and management Cancer 49 1 177 187
9. PG Casali P Picci 2005 Adjuvant chemotherapy for soft tissue sarcoma Curr Opin Oncol 17 4 361 365
10. CD Blanke CL Corless 2005 State-of-the art therapy for gastrointestinal stromal tumors Cancer Invest 23 3 274 280
11. U De Giorgi J Verweij 2005 Imatinib and gastrointestinal stromal tumors: where do we go from here? Mol Cancer Ther 4 3 495 501
12. P Therasse SG Arbuck EA Eisenhauer 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 3 205 216
13. BP Rubin MC Heinrich CL Corless 2007 Gastrointestinal stromal tumour Lancet 369 9574 1731 1741
14. DG Savage KH Antman 2002 Imatinib mesylate-a new oral targeted therapy N Engl J Med 346 9 683 693
15. JS Gold RP Dematteo 2006 Combined surgical and molecular therapy: the gastrointestinal stromal tumor model Ann Surg 244 2 176 184
16. JP Pierie U Choudry A Muzikansky BY Yeap WW Souba MJ Ott 2001 The effect of surgery and grade on outcome of gastrointestinal stromal tumors Arch Surg 136 4 383 389
17. RP DeMatteo JJ Lewis D Leung SS Mudan JM Woodruff MF Brennan 2000 Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival Ann Surg 231 1 51 58
18. JS Gold SM van der Zwan M Gonen 2007 Outcome of metastatic GIST in the era before tyrosine kinase inhibitors Ann Surg Oncol 14 1 134 142
19. RP DeMatteo MC Heinrich WM El-Rifai G Demetri 2002 Clinical management of gastrointestinal stromal tumors: before and after STI-571 Hum Pathol 33 5 466 477
20. DeMatteo RP, Maki R. Adjuvant imatinib mesylate increases recurrence free survival (RFS) in patients with completely resected localized primary gastrointestinal stromal tumor (GIST): North American Intergroup Phase III trial ACOSOG Z900. J Clin Oncol 2007;25:10079 (Abstract).
21. RP DeMatteo RG Maki S Singer M Gonen MF Brennan CR Antonescu 2007 Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor Ann Surg 245 3 347 352
22. GD Demetri M von Mehren CD Blanke 2002 Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors N Engl J Med 347 7 472 480
23. J Verweij PG Casali J Zalcberg 2004 Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial Lancet 364 9440 1127 1134
24. P Rutkowski ZI Nowecki W Michej 2007 Risk criteria and prognostic factors for predicting recurrences after resection of primary gastrointestinal stromal tumor Ann Surg Oncol 14 7 2018 2027
25. EA Perez JC Gutierrez X Jin 2007 Surgical outcomes of gastrointestinal sarcoma including gastrointestinal stromal tumors: a population-based examination J Gastrointest Surg 11 1 114 125
26. M Miettinen J Lasota 2006 Gastrointestinal stromal tumors: pathology and prognosis at different sites Semin Diagn Pathol 23 2 70 83
27. TS Emory LH Sobin L Lukes DH Lee TJ O'Leary 1999 Prognosis of gastrointestinal smooth-muscle (stromal) tumors: dependence on anatomic site Am J Surg Pathol 23 1 82 87
28. T Ueyama KJ Guo H Hashimoto Y Daimaru M Enjoji 1992 A clinicopathologic and immunohistochemical study of gastrointestinal stromal tumors Cancer 69 4 947 955
29. EH Ng RE Pollock MF Munsell EN Atkinson MM Romsdahl 1992 Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging Ann Surg 215 1 68 77
30. YW Novitsky KW Kercher RF Sing BT Heniford 2006 Long-term outcomes of laparoscopic resection of gastric gastrointestinal stromal tumors Ann Surg 243 6 738 745 discussion 45-47)
31. C Langer B Gunawan P Schuler W Huber L Fuzesi H Becker 2003 Prognostic factors influencing surgical management and outcome of gastrointestinal stromal tumours Br J Surg 90 3 332 339
32. JA Crosby CN Catton A Davis 2001 Malignant gastrointestinal stromal tumors of the small intestine: a review of 50 cases from a prospective database Ann Surg Oncol 8 1 50 59
33. RH Andtbacka CS Ng CL Scaife 2007 Surgical resection of gastrointestinal stromal tumors after treatment with imatinib Ann Surg Oncol 14 1 14 24
34. JY Blay S Bonvalot P Casali 2005 Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO Ann Oncol 16 4 566 578
35. CP Raut M Posner J Desai 2006 Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors J Clin Oncol 24 15 2325 2331
36. B Nilsson K Sjolund LG Kindblom 2007 Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST) Br J Cancer 96 11 1656 1658
37. LL Chen M Sabripour RH Andtbacka 2005 Imatinib resistance in gastrointestinal stromal tumors Curr Oncol Rep 7 4 293 299
38. M Debiec-Rychter J Cools H Dumez 2005 Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants Gastroenterology 128 2 270 279
39. JY Blay A Le Cesne I Ray-Coquard 2007 Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group J Clin Oncol 25 9 1107 1113
40. GD Demetri AT van Oosterom CR Garrett 2006 Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial Lancet 368 9544 1329 1338